Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Company Deals

Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates

Fineline Cube Sep 28, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...

Company Drug

Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy

Fineline Cube Sep 28, 2023

The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...

Company Medical Device

Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform

Fineline Cube Sep 28, 2023

Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...

Company Medical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

Fineline Cube Sep 28, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...

Company Deals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

Fineline Cube Sep 28, 2023

China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...

Company Drug

Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China

Fineline Cube Sep 28, 2023

US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...

Company Drug

Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment

Fineline Cube Sep 28, 2023

Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...

Company Medical Device

Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Sep 28, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Drug

Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review

Fineline Cube Sep 28, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...

Company Drug

Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009

Fineline Cube Sep 28, 2023

Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...

Company Deals

Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline

Fineline Cube Sep 28, 2023

China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...

Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47

Fineline Cube Sep 28, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...

Company Deals

MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices

Fineline Cube Sep 28, 2023

MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...

Company Drug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

Fineline Cube Sep 28, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...

Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Posts pagination

1 … 406 407 408 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.